{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:53:22Z","timestamp":1794282802683,"version":"4.9.0"},"reference-count":252,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41575-025-01089-1","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:25:05Z","timestamp":1751865905000},"page":"619-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-2909","authenticated-orcid":false,"given":"Harry Cheuk-Hay","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3435-6550","authenticated-orcid":false,"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"1089_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi, A. et al. The gut\u2013liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15, 397\u2013411 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1089_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J. Hepatol. 72, 558\u2013577 (2020).","journal-title":"J. Hepatol."},{"key":"1089_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","volume":"21","author":"CL Hsu","year":"2023","unstructured":"Hsu, C. L. & Schnabl, B. The gut\u2013liver axis and gut microbiota in health and liver disease. Nat. Rev. Microbiol. 21, 719\u2013733 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1089_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224 (2021).","journal-title":"Lancet"},{"key":"1089_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh, S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13, 643\u2013654.e9 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1089_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"1089_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cgh.2013.02.015","volume":"11","author":"M Raman","year":"2013","unstructured":"Raman, M. et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 11, 868\u2013875.e3 (2013).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1089_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062885","volume":"8","author":"VW Wong","year":"2013","unstructured":"Wong, V. W. et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis \u2014 a longitudinal study. PLoS ONE\u00a08, e62885 (2013).","journal-title":"PLoS ONE"},{"key":"1089_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","volume":"16","author":"F Shen","year":"2017","unstructured":"Shen, F. et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat. Dis. Int. 16, 375\u2013381 (2017).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"1089_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601\u2013609 (2013).","journal-title":"Hepatology"},{"key":"1089_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky, J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 17, 279\u2013297 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1089_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18754-5","volume":"11","author":"G Lee","year":"2020","unstructured":"Lee, G. et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat. Commun. 11, 4982 (2020).","journal-title":"Nat. Commun."},{"key":"1089_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054\u20131062.e5 (2017).","journal-title":"Cell Metab."},{"key":"1089_CR14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","volume":"24","author":"L Hoyles","year":"2018","unstructured":"Hoyles, L. et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat. Med. 24, 1070\u20131080 (2018).","journal-title":"Nat. Med."},{"key":"1089_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.32197","volume":"75","author":"SY Kwan","year":"2022","unstructured":"Kwan, S. Y. et al. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology 75, 955\u2013967 (2022).","journal-title":"Hepatology"},{"key":"1089_CR16","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","volume":"78","author":"RM Carr","year":"2023","unstructured":"Carr, R. M. et al. An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology 78, 1843\u20131857 (2023).","journal-title":"Hepatology"},{"key":"1089_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","volume":"157","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer, J. B. et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 157, 1109\u20131122 (2019).","journal-title":"Gastroenterology"},{"key":"1089_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1080\/17474124.2022.2016391","volume":"15","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Expert Rev. Gastroenterol. Hepatol. 15, 1401\u20131409 (2021).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"1089_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.eng.2022.10.010","volume":"35","author":"X Zeng","year":"2024","unstructured":"Zeng, X. et al. Pien Tze Huang protects against non-alcoholic steatohepatitis by modulating the gut microbiota and metabolites in mice. Engineering 35, 257\u2013269 (2024).","journal-title":"Engineering"},{"key":"1089_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12866-016-0667-x","volume":"16","author":"A Kajikawa","year":"2016","unstructured":"Kajikawa, A. et al. Characterization of flagellins isolated from a highly motile strain of Lactobacillus agilis. BMC Microbiol. 16, 49 (2016).","journal-title":"BMC Microbiol."},{"key":"1089_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","volume":"15","author":"D Kim","year":"2017","unstructured":"Kim, D. & Kim, W. R. Nonobese fatty liver disease. Clin. Gastroenterol. Hepatol. 15, 474\u2013485 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1089_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.28697","volume":"65","author":"JC Leung","year":"2017","unstructured":"Leung, J. C. et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology 65, 54\u201364 (2017).","journal-title":"Hepatology"},{"key":"1089_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.numecd.2017.10.014","volume":"28","author":"SMB Duarte","year":"2018","unstructured":"Duarte, S. M. B. et al. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study. Nutr. Metab. Cardiovasc. Dis. 28, 369\u2013384 (2018).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1089_CR24","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/jgh.15487","volume":"36","author":"M Iwaki","year":"2021","unstructured":"Iwaki, M. et al. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 36, 2275\u20132284 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1089_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/biomedicines9101346","volume":"9","author":"MS Kuchay","year":"2021","unstructured":"Kuchay, M. S., Martinez-Montoro, J. I., Choudhary, N. S., Fernandez-Garcia, J. C. & Ramos-Molina, B. Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges. Biomedicines 9, 1346 (2021).","journal-title":"Biomedicines"},{"key":"1089_CR26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/jgh.12996","volume":"30","author":"Y Ha","year":"2015","unstructured":"Ha, Y. et al. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: a case-control study. J. Gastroenterol. Hepatol. 30, 1666\u20131672 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1089_CR27","doi-asserted-by":"publisher","first-page":"17932","DOI":"10.3748\/wjg.v20.i47.17932","volume":"20","author":"RN Feng","year":"2014","unstructured":"Feng, R. N. et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J. Gastroenterol. 20, 17932\u201317940 (2014).","journal-title":"World J. Gastroenterol."},{"key":"1089_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59\u201364 (2014).","journal-title":"Nature"},{"key":"1089_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","volume":"69","author":"FR Ponziani","year":"2019","unstructured":"Ponziani, F. R. et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69, 107\u2013120 (2019).","journal-title":"Hepatology"},{"key":"1089_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09455-9","volume":"10","author":"C Caussy","year":"2019","unstructured":"Caussy, C. et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat. Commun. 10, 1406 (2019).","journal-title":"Nat. Commun."},{"key":"1089_CR31","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","volume":"32","author":"TG Oh","year":"2020","unstructured":"Oh, T. G. et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 32, 878\u2013888.e6 (2020).","journal-title":"Cell Metab."},{"key":"1089_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20422-7","volume":"12","author":"J Behary","year":"2021","unstructured":"Behary, J. et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat. Commun. 12, 187 (2021).","journal-title":"Nat. Commun."},{"key":"1089_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/gutjnl-2014-307649","volume":"65","author":"E Quevrain","year":"2016","unstructured":"Quevrain, E. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn\u2019s disease. Gut 65, 415\u2013425 (2016).","journal-title":"Gut"},{"key":"1089_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.chom.2022.07.003","volume":"30","author":"H Lu","year":"2022","unstructured":"Lu, H. et al. Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4\/MyD88\/NF-\u03baB axis. Cell Host Microbe 30, 1139\u20131150.e7 (2022).","journal-title":"Cell Host Microbe"},{"key":"1089_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12331","volume":"500","author":"K Atarashi","year":"2013","unstructured":"Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232\u2013236 (2013).","journal-title":"Nature"},{"key":"1089_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4161\/gmic.28572","volume":"5","author":"S Narushima","year":"2014","unstructured":"Narushima, S. et al. Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia. Gut Microbes 5, 333\u2013339 (2014).","journal-title":"Gut Microbes"},{"key":"1089_CR37","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41591-019-0485-4","volume":"25","author":"J Scheiman","year":"2019","unstructured":"Scheiman, J. et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. Nat. Med. 25, 1104\u20131109 (2019).","journal-title":"Nat. Med."},{"key":"1089_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk0855","volume":"14","author":"H Leung","year":"2022","unstructured":"Leung, H. et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci. Transl Med. 14, eabk0855 (2022).","journal-title":"Sci. Transl Med."},{"key":"1089_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nature25973","volume":"555","author":"D Rothschild","year":"2018","unstructured":"Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210\u2013215 (2018).","journal-title":"Nature"},{"key":"1089_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature11053","volume":"486","author":"T Yatsunenko","year":"2012","unstructured":"Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222\u2013227 (2012).","journal-title":"Nature"},{"key":"1089_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature08821","volume":"464","author":"J Qin","year":"2010","unstructured":"Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59\u201365 (2010).","journal-title":"Nature"},{"key":"1089_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nature09944","volume":"473","author":"M Arumugam","year":"2011","unstructured":"Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174\u2013180 (2011).","journal-title":"Nature"},{"key":"1089_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3684","volume":"14","author":"DM Underhill","year":"2014","unstructured":"Underhill, D. M. & Iliev, I. D. The mycobiota: interactions between commensal fungi and the host immune system. Nat. Rev. Immunol. 14, 405\u2013416 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"1089_CR44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/oby.23073","volume":"29","author":"N You","year":"2021","unstructured":"You, N. et al. Fecal fungi dysbiosis in nonalcoholic fatty liver disease. Obesity 29, 350\u2013358 (2021).","journal-title":"Obesity"},{"key":"1089_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","volume":"76","author":"M Demir","year":"2022","unstructured":"Demir, M. et al. The fecal mycobiome in non-alcoholic fatty liver disease. J. Hepatol. 76, 788\u2013799 (2022).","journal-title":"J. Hepatol."},{"key":"1089_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1157368","volume":"13","author":"C Niu","year":"2023","unstructured":"Niu, C. et al. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease. Front. Cell Infect. Microbiol. 13, 1157368 (2023).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1089_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2307586","volume":"16","author":"G Viebahn","year":"2024","unstructured":"Viebahn, G. et al. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease. Gut Microbes 16, 2307586 (2024).","journal-title":"Gut Microbes"},{"key":"1089_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/0974-2700.42203","volume":"1","author":"J Pak","year":"2008","unstructured":"Pak, J., Tucci, V. T., Vincent, A. L., Sandin, R. L. & Greene, J. N. Mucormycosis in immunochallenged patients. J. Emerg. Trauma Shock 1, 106\u2013113 (2008).","journal-title":"J. Emerg. Trauma Shock"},{"key":"1089_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/21505594.2021.2019950","volume":"13","author":"JP Lopes","year":"2022","unstructured":"Lopes, J. P. & Lionakis, M. S. Pathogenesis and virulence of Candida albicans. Virulence 13, 89\u2013121 (2022).","journal-title":"Virulence"},{"key":"1089_CR50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.chom.2018.10.002","volume":"24","author":"E Guerin","year":"2018","unstructured":"Guerin, E. et al. Biology and taxonomy of crass-like bacteriophages, the most abundant virus in the human gut. Cell Host Microbe 24, 653\u2013664.e6 (2018).","journal-title":"Cell Host Microbe"},{"key":"1089_CR51","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","volume":"159","author":"S Lang","year":"2020","unstructured":"Lang, S. et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology 159, 1839\u20131852 (2020).","journal-title":"Gastroenterology"},{"key":"1089_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","volume":"186","author":"SA Strathdee","year":"2023","unstructured":"Strathdee, S. A., Hatfull, G. F., Mutalik, V. K. & Schooley, R. T. Phage therapy: from biological mechanisms to future directions. Cell 186, 17\u201331 (2023).","journal-title":"Cell"},{"key":"1089_CR53","doi-asserted-by":"publisher","first-page":"10400","DOI":"10.1073\/pnas.1601060113","volume":"113","author":"P Manrique","year":"2016","unstructured":"Manrique, P. et al. Healthy human gut phageome. Proc. Natl Acad. Sci. USA 113, 10400\u201310405 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1089_CR54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.chom.2019.09.009","volume":"26","author":"AN Shkoporov","year":"2019","unstructured":"Shkoporov, A. N. et al. The human gut virome is highly diverse, stable, and individual specific. Cell Host Microbe 26, 527\u2013541.e5 (2019).","journal-title":"Cell Host Microbe"},{"key":"1089_CR55","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.chom.2019.01.017","volume":"25","author":"AN Shkoporov","year":"2019","unstructured":"Shkoporov, A. N. & Hill, C. Bacteriophages of the human gut: the \u201cKnown Unknown\u201d of the microbiome. Cell Host Microbe 25, 195\u2013209 (2019).","journal-title":"Cell Host Microbe"},{"key":"1089_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13100-017-0095-y","volume":"8","author":"V Aggarwala","year":"2017","unstructured":"Aggarwala, V., Liang, G. & Bushman, F. D. Viral communities of the human gut: metagenomic analysis of composition and dynamics. Mob. DNA 8, 12 (2017).","journal-title":"Mob. DNA"},{"key":"1089_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151725","volume":"132","author":"JC Leinwand","year":"2022","unstructured":"Leinwand, J. C. et al. Intrahepatic microbes govern liver immunity by programming NKT cells. J. Clin. Invest. 132, e151725 (2022).","journal-title":"J. Clin. Invest."},{"key":"1089_CR58","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","volume":"69","author":"S Sookoian","year":"2020","unstructured":"Sookoian, S. et al. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 69, 1483\u20131491 (2020).","journal-title":"Gut"},{"key":"1089_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003069","volume":"10","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma. J. Immunother. Cancer 10, e003069 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1089_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1331","volume":"13","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery. Clin. Transl Med. 13, e1331 (2023).","journal-title":"Clin. Transl Med."},{"key":"1089_CR61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41564-024-01890-9","volume":"10","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice. Nat. Microbiol. 10, 169\u2013184 (2025).","journal-title":"Nat. Microbiol."},{"key":"1089_CR62","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00983-22","volume":"10","author":"JH Huang","year":"2022","unstructured":"Huang, J. H. et al. The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma. Microbiol. Spectr. 10, e0098322 (2022).","journal-title":"Microbiol. Spectr."},{"key":"1089_CR63","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12967-023-03938-6","volume":"21","author":"Y He","year":"2023","unstructured":"He, Y., Zhang, Q., Yu, X., Zhang, S. & Guo, W. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. J. Transl Med. 21, 68 (2023).","journal-title":"J. Transl Med."},{"key":"1089_CR64","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/HEP.0000000000000427","volume":"78","author":"S Li","year":"2023","unstructured":"Li, S. et al. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC. Hepatology 78, 1079\u20131091 (2023).","journal-title":"Hepatology"},{"key":"1089_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000182","volume":"7","author":"M Effenberger","year":"2023","unstructured":"Effenberger, M. et al. A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma. Hepatol. Commun. 7, e00182 (2023).","journal-title":"Hepatol. Commun."},{"key":"1089_CR66","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.3390\/nu14245335","volume":"14","author":"W Guo","year":"2022","unstructured":"Guo, W. et al. Diet and risk of non-alcoholic fatty liver disease, cirrhosis, and liver cancer: a large prospective cohort study in UK Biobank. Nutrients 14, 5335 (2022).","journal-title":"Nutrients"},{"key":"1089_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02793-y","volume":"21","author":"F Petermann-Rocha","year":"2023","unstructured":"Petermann-Rocha, F. et al. Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants. BMC Med. 21, 123 (2023).","journal-title":"BMC Med."},{"key":"1089_CR68","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"1089_CR69","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity.","year":"2024","unstructured":"European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"1089_CR70","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/nu13010172","volume":"13","author":"ES George","year":"2021","unstructured":"George, E. S. et al. The association between diet and hepatocellular carcinoma: a systematic review. Nutrients 13, 172 (2021).","journal-title":"Nutrients"},{"key":"1089_CR71","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","volume":"70","author":"A Yaskolka Meir","year":"2021","unstructured":"Yaskolka Meir, A. et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut 70, 2085\u20132095 (2021).","journal-title":"Gut"},{"key":"1089_CR72","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/hep.32207","volume":"75","author":"E Vilar-Gomez","year":"2022","unstructured":"Vilar-Gomez, E. et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology 75, 1491\u20131506 (2022).","journal-title":"Hepatology"},{"key":"1089_CR73","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 70, 761\u2013774 (2021).","journal-title":"Gut"},{"key":"1089_CR74","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41564-023-01418-7","volume":"8","author":"W Wei","year":"2023","unstructured":"Wei, W. et al. Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid. Nat. Microbiol. 8, 1534\u20131548 (2023).","journal-title":"Nat. Microbiol."},{"key":"1089_CR75","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","volume":"75","author":"NF Lange","year":"2021","unstructured":"Lange, N. F., Radu, P. & Dufour, J. F. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J. Hepatol. 75, 1217\u20131227 (2021).","journal-title":"J. Hepatol."},{"key":"1089_CR76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","volume":"610","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature 610, 562\u2013568 (2022).","journal-title":"Nature"},{"key":"1089_CR77","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-pathmechdis-111523-023430","volume":"20","author":"X Zhang","year":"2025","unstructured":"Zhang, X., Chang, K. M., Yu, J. & Loomba, R. Unraveling mechanisms of genetic risks in metabolic dysfunction-associated steatotic liver diseases: a pathway to precision medicine. Annu. Rev. Pathol. 20, 375\u2013403 (2025).","journal-title":"Annu. Rev. Pathol."},{"key":"1089_CR78","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","volume":"74","author":"S Ha","year":"2025","unstructured":"Ha, S., Wong, V. W., Zhang, X. & Yu, J. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut 74, 141\u2013152\u00a0(2025).","journal-title":"Gut"},{"key":"1089_CR79","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s42255-024-01177-7","volume":"7","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. Nat. Metab. 7, 102\u2013119 (2025).","journal-title":"Nat. Metab."},{"key":"1089_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-15","volume":"7","author":"AL Harte","year":"2010","unstructured":"Harte, A. L. et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. 7, 15 (2010).","journal-title":"J. Inflamm."},{"key":"1089_CR81","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/MCG.0b013e3181e12c24","volume":"45","author":"FJ Verdam","year":"2011","unstructured":"Verdam, F. J., Rensen, S. S., Driessen, A., Greve, J. W. & Buurman, W. A. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 45, 149\u2013152 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"1089_CR82","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.dld.2014.02.010","volume":"46","author":"V Giorgio","year":"2014","unstructured":"Giorgio, V. et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig. Liver Dis. 46, 556\u2013560 (2014).","journal-title":"Dig. Liver Dis."},{"key":"1089_CR83","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/s11695-007-9243-7","volume":"17","author":"AG Ruiz","year":"2007","unstructured":"Ruiz, A. G. et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 17, 1374\u20131380 (2007).","journal-title":"Obes. Surg."},{"key":"1089_CR84","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","volume":"49","author":"L Miele","year":"2009","unstructured":"Miele, L. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877\u20131887 (2009).","journal-title":"Hepatology"},{"key":"1089_CR85","first-page":"136","volume":"61","author":"D Xin","year":"2014","unstructured":"Xin, D., Zong-Shun, L., Bang-Mao, W. & Lu, Z. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease. Hepatogastroenterology 61, 136\u2013140 (2014).","journal-title":"Hepatogastroenterology"},{"key":"1089_CR86","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","volume":"151","author":"K Rahman","year":"2016","unstructured":"Rahman, K. et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 151, 733\u2013746.e12 (2016).","journal-title":"Gastroenterology"},{"key":"1089_CR87","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","volume":"71","author":"J Mouries","year":"2019","unstructured":"Mouries, J. et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J. Hepatol. 71, 1216\u20131228 (2019).","journal-title":"J. Hepatol."},{"key":"1089_CR88","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000492853","volume":"49","author":"Y Feng","year":"2018","unstructured":"Feng, Y., Wang, Y., Wang, P., Huang, Y. & Wang, F. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy. Cell Physiol. Biochem. 49, 190\u2013205 (2018).","journal-title":"Cell Physiol. Biochem."},{"key":"1089_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07859-7","volume":"10","author":"R Singh","year":"2019","unstructured":"Singh, R. et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat. Commun. 10, 89 (2019).","journal-title":"Nat. Commun."},{"key":"1089_CR90","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jcmgh.2021.02.007","volume":"11","author":"S Ghosh","year":"2021","unstructured":"Ghosh, S., Whitley, C. S., Haribabu, B. & Jala, V. R. Regulation of intestinal barrier function by microbial metabolites. Cell Mol. Gastroenterol. Hepatol. 11, 1463\u20131482 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1089_CR91","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fmicb.2014.00674","volume":"5","author":"DA Ravcheev","year":"2014","unstructured":"Ravcheev, D. A. & Thiele, I. Systematic genomic analysis reveals the complementary aerobic and anaerobic respiration capacities of the human gut microbiota. Front. Microbiol. 5, 674 (2014).","journal-title":"Front. Microbiol."},{"key":"1089_CR92","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4829180","volume":"2017","author":"D Patel","year":"2017","unstructured":"Patel, D. & Witt, S. N. Ethanolamine and phosphatidylethanolamine: partners in health and disease. Oxid. Med. Cell Longev. 2017, 4829180 (2017).","journal-title":"Oxid. Med. Cell Longev."},{"key":"1089_CR93","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1136\/gutjnl-2022-327365","volume":"72","author":"SP Mishra","year":"2023","unstructured":"Mishra, S. P. et al. A mechanism by which gut microbiota elevates permeability and inflammation in obese\/diabetic mice and human gut. Gut 72, 1848\u20131865 (2023).","journal-title":"Gut"},{"key":"1089_CR94","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao, N. et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 67, 1881\u20131891 (2018).","journal-title":"Gut"},{"key":"1089_CR95","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/hep.32568","volume":"76","author":"E Smirnova","year":"2022","unstructured":"Smirnova, E. et al. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD. Hepatology 76, 1811\u20131824 (2022).","journal-title":"Hepatology"},{"key":"1089_CR96","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12347","volume":"499","author":"S Yoshimoto","year":"2013","unstructured":"Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97\u2013101 (2013).","journal-title":"Nature"},{"key":"1089_CR97","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.30219","volume":"139","author":"G Xie","year":"2016","unstructured":"Xie, G. et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int. J. Cancer 139, 1764\u20131775 (2016).","journal-title":"Int. J. Cancer"},{"key":"1089_CR98","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","volume":"15","author":"W Jia","year":"2018","unstructured":"Jia, W., Xie, G. & Jia, W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111\u2013128 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1089_CR99","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-16-0932","volume":"7","author":"TM Loo","year":"2017","unstructured":"Loo, T. M. et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov. 7, 522\u2013538 (2017).","journal-title":"Cancer Discov."},{"key":"1089_CR100","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1039\/C8FO01143E","volume":"9","author":"L Liu","year":"2018","unstructured":"Liu, L. et al. Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis. Food Funct. 9, 5588\u20135597 (2018).","journal-title":"Food Funct."},{"key":"1089_CR101","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138881","volume":"5","author":"H Zhou","year":"2020","unstructured":"Zhou, H. et al. Bile acid toxicity in Paneth cells contributes to gut dysbiosis induced by high-fat feeding. JCI Insight 5, e138881 (2020).","journal-title":"JCI Insight"},{"key":"1089_CR102","doi-asserted-by":"publisher","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, eaan5931 (2018).","journal-title":"Science"},{"key":"1089_CR103","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","volume":"35","author":"J Kuang","year":"2023","unstructured":"Kuang, J. et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. Cell Metab. 35, 1752\u20131766.e8 (2023).","journal-title":"Cell Metab."},{"key":"1089_CR104","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","volume":"187","author":"Q Nie","year":"2024","unstructured":"Nie, Q. et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway. Cell 187, 2717\u20132734.e33 (2024).","journal-title":"Cell"},{"key":"1089_CR105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","volume":"15","author":"EE Canfora","year":"2019","unstructured":"Canfora, E. E., Meex, R. C. R., Venema, K. & Blaak, E. E. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat. Rev. Endocrinol. 15, 261\u2013273 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1089_CR106","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/gutjnl-2014-307913","volume":"64","author":"ES Chambers","year":"2015","unstructured":"Chambers, E. S. et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64, 1744\u20131754 (2015).","journal-title":"Gut"},{"key":"1089_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-021-01125-7","volume":"9","author":"R Aoki","year":"2021","unstructured":"Aoki, R. et al. Commensal microbe-derived acetate suppresses NAFLD\/NASH development via hepatic FFAR2 signalling in mice. Microbiome 9, 188 (2021).","journal-title":"Microbiome"},{"key":"1089_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-023-00451-y","volume":"9","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Inulin-enriched Megamonas funiformis ameliorates metabolic dysfunction-associated fatty liver disease by producing propionic acid. npj\u00a0Biofilms Microbiomes 9, 84 (2023).","journal-title":"npj\u00a0Biofilms Microbiomes"},{"key":"1089_CR109","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/db08-1637","volume":"58","author":"Z Gao","year":"2009","unstructured":"Gao, Z. et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509\u20131517 (2009).","journal-title":"Diabetes"},{"key":"1089_CR110","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jcmgh.2021.05.006","volume":"12","author":"ZH Zhao","year":"2021","unstructured":"Zhao, Z. H. et al. Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene. Cell Mol. Gastroenterol. Hepatol. 12, 857\u2013871 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1089_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.982222","volume":"13","author":"JK Xia","year":"2022","unstructured":"Xia, J. K. et al. Roles and regulation of histone acetylation in hepatocellular carcinoma. Front. Genet. 13, 982222 (2022).","journal-title":"Front. Genet."},{"key":"1089_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110226","volume":"128","author":"KS Olaniyi","year":"2020","unstructured":"Olaniyi, K. S. & Amusa, O. A. Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats. Biomed. Pharmacother. 128, 110226 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"1089_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05853-6","volume":"14","author":"A Sarkar","year":"2023","unstructured":"Sarkar, A. et al. Butyrate limits inflammatory macrophage niche in NASH. Cell Death Dis. 14, 332 (2023).","journal-title":"Cell Death Dis."},{"key":"1089_CR114","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","volume":"79","author":"Q Song","year":"2023","unstructured":"Song, Q. et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J. Hepatol. 79, 1352\u20131365 (2023).","journal-title":"J. Hepatol."},{"key":"1089_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104952","volume":"100","author":"HC Lau","year":"2024","unstructured":"Lau, H. C. et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. EBioMedicine 100, 104952 (2024).","journal-title":"EBioMedicine"},{"key":"1089_CR116","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/j.gastro.2013.04.056","volume":"145","author":"MH Kim","year":"2013","unstructured":"Kim, M. H., Kang, S. G., Park, J. H., Yanagisawa, M. & Kim, C. H. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 145, 396\u2013406.e10 (2013).","journal-title":"Gastroenterology"},{"key":"1089_CR117","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.cell.2014.04.051","volume":"158","author":"A Belcheva","year":"2014","unstructured":"Belcheva, A. et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158, 288\u2013299 (2014).","journal-title":"Cell"},{"key":"1089_CR118","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cmet.2015.09.028","volume":"22","author":"V Singh","year":"2015","unstructured":"Singh, V. et al. Microbiota-dependent hepatic lipogenesis mediated by stearoyl CoA desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-deficient mice. Cell Metab. 22, 983\u2013996 (2015).","journal-title":"Cell Metab."},{"key":"1089_CR119","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2018.09.004","volume":"175","author":"V Singh","year":"2018","unstructured":"Singh, V. et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell 175, 679\u2013694.e22 (2018).","journal-title":"Cell"},{"key":"1089_CR120","doi-asserted-by":"publisher","first-page":"16767","DOI":"10.1073\/pnas.0808567105","volume":"105","author":"BS Samuel","year":"2008","unstructured":"Samuel, B. S. et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. USA 105, 16767\u201316772 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1089_CR121","doi-asserted-by":"publisher","first-page":"E211","DOI":"10.1152\/ajpendo.00229.2010","volume":"300","author":"M Bjursell","year":"2011","unstructured":"Bjursell, M. et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 300, E211\u2013E220 (2011).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1089_CR122","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","volume":"68","author":"H Chu","year":"2019","unstructured":"Chu, H., Duan, Y., Yang, L. & Schnabl, B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut 68, 359\u2013370 (2019).","journal-title":"Gut"},{"key":"1089_CR123","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","volume":"6","author":"M Rau","year":"2018","unstructured":"Rau, M. et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol. J. 6, 1496\u20131507 (2018).","journal-title":"United European Gastroenterol. J."},{"key":"1089_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femsec\/fiu002","volume":"91","author":"S Michail","year":"2015","unstructured":"Michail, S. et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol. Ecol. 91, 1\u20139 (2015).","journal-title":"FEMS Microbiol. Ecol."},{"key":"1089_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36256-y","volume":"14","author":"K Deng","year":"2023","unstructured":"Deng, K. et al. Comparison of fecal and blood metabolome reveals inconsistent associations of the gut microbiota with cardiometabolic diseases. Nat. Commun. 14, 571 (2023).","journal-title":"Nat. Commun."},{"key":"1089_CR126","doi-asserted-by":"publisher","DOI":"10.1177\/1178646917691938","volume":"10","author":"AA Badawy","year":"2017","unstructured":"Badawy, A. A. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int. J. Tryptophan Res. 10, 1178646917691938 (2017).","journal-title":"Int. J. Tryptophan Res."},{"key":"1089_CR127","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","volume":"23","author":"A Agus","year":"2018","unstructured":"Agus, A., Planchais, J. & Sokol, H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716\u2013724 (2018).","journal-title":"Cell Host Microbe"},{"key":"1089_CR128","doi-asserted-by":"publisher","first-page":"21309","DOI":"10.18632\/aging.203460","volume":"13","author":"G Sui","year":"2021","unstructured":"Sui, G., Jia, L., Quan, D., Zhao, N. & Yang, G. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. Aging 13, 21309\u201321324 (2021).","journal-title":"Aging"},{"key":"1089_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14279","volume":"54","author":"C Arto","year":"2024","unstructured":"Arto, C. et al. Metabolic profiling of tryptophan pathways: implications for obesity and metabolic dysfunction-associated steatotic liver disease. Eur. J. Clin. Invest. 54, e14279 (2024).","journal-title":"Eur. J. Clin. Invest."},{"key":"1089_CR130","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fphar.2020.00553","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Gut-derived serotonin contributes to the progression of non-alcoholic steatohepatitis via the liver HTR2A\/PPAR\u03b32 pathway. Front. Pharmacol. 11, 553 (2020).","journal-title":"Front. Pharmacol."},{"key":"1089_CR131","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/hep4.1665","volume":"5","author":"K Wegermann","year":"2021","unstructured":"Wegermann, K. et al. Serum bile acid, vitamin E, and serotonin metabolites are associated with future liver-related events in nonalcoholic fatty liver disease. Hepatol. Commun. 5, 608\u2013617 (2021).","journal-title":"Hepatol. Commun."},{"key":"1089_CR132","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197\u2013203 (2011).","journal-title":"Nature"},{"key":"1089_CR133","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/1521-4141(200108)31:8<2313::AID-IMMU2313>3.0.CO;2-S","volume":"31","author":"S Fujigaki","year":"2001","unstructured":"Fujigaki, S. et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-\u03b3-independent mechanism. Eur. J. Immunol. 31, 2313\u20132318 (2001).","journal-title":"Eur. J. Immunol."},{"key":"1089_CR134","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41591-018-0060-4","volume":"24","author":"L Laurans","year":"2018","unstructured":"Laurans, L. et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat. Med. 24, 1113\u20131120 (2018).","journal-title":"Nat. Med."},{"key":"1089_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07287-7","volume":"9","author":"W Choi","year":"2018","unstructured":"Choi, W. et al. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat. Commun. 9, 4824 (2018).","journal-title":"Nat. Commun."},{"key":"1089_CR136","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nm.3766","volume":"21","author":"JD Crane","year":"2015","unstructured":"Crane, J. D. et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat. Med. 21, 166\u2013172 (2015).","journal-title":"Nat. Med."},{"key":"1089_CR137","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/advances\/nmz127","volume":"11","author":"K Gao","year":"2020","unstructured":"Gao, K., Mu, C. L., Farzi, A. & Zhu, W. Y. Tryptophan metabolism: a link between the gut microbiota and brain. Adv. Nutr. 11, 709\u2013723 (2020).","journal-title":"Adv. Nutr."},{"key":"1089_CR138","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nm.4106","volume":"22","author":"V Rothhammer","year":"2016","unstructured":"Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586\u2013597 (2016).","journal-title":"Nat. Med."},{"key":"1089_CR139","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41575-021-00430-8","volume":"18","author":"B Stockinger","year":"2021","unstructured":"Stockinger, B., Shah, K. & Wincent, E. AHR in the intestinal microenvironment: safeguarding barrier function. Nat. Rev. Gastroenterol. Hepatol. 18, 559\u2013570 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1089_CR140","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/hep.31115","volume":"72","author":"L Ma","year":"2020","unstructured":"Ma, L. et al. Indole alleviates diet-induced hepatic steatosis and inflammation in a manner involving myeloid cell 6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 3. Hepatology 72, 1191\u20131203 (2020).","journal-title":"Hepatology"},{"key":"1089_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.634","volume":"11","author":"JS Yu","year":"2021","unstructured":"Yu, J. S. et al. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease. Clin. Transl Med. 11, e634 (2021).","journal-title":"Clin. Transl Med."},{"key":"1089_CR142","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.3390\/nu11092062","volume":"11","author":"Y Ji","year":"2019","unstructured":"Ji, Y., Gao, Y., Chen, H., Yin, Y. & Zhang, W. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. Nutrients 11, 2062 (2019).","journal-title":"Nutrients"},{"key":"1089_CR143","first-page":"1","volume":"51","author":"ZH Zhao","year":"2021","unstructured":"Zhao, Z. H. et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp. Mol. Med. 51, 1\u201314 (2019).","journal-title":"Exp. Mol. Med."},{"key":"1089_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2022.109041","volume":"107","author":"B Zhu","year":"2022","unstructured":"Zhu, B. et al. Indole supplementation ameliorates MCD-induced NASH in mice. J. Nutr. Biochem. 107, 109041 (2022).","journal-title":"J. Nutr. Biochem."},{"key":"1089_CR145","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2217\/fmb-2023-0250","volume":"19","author":"B Mbaye","year":"2024","unstructured":"Mbaye, B. et al. A catalog of ethanol-producing microbes in humans. Future Microbiol. 19, 697\u2013714 (2024).","journal-title":"Future Microbiol."},{"key":"1089_CR146","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","volume":"30","author":"J Yuan","year":"2019","unstructured":"Yuan, J. et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 30, 675\u2013688.e7 (2019).","journal-title":"Cell Metab."},{"key":"1089_CR147","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","volume":"28","author":"AS Meijnikman","year":"2022","unstructured":"Meijnikman, A. S. et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat. Med. 28, 2100\u20132106 (2022).","journal-title":"Nat. Med."},{"key":"1089_CR148","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.3390\/cells11213390","volume":"11","author":"B Mbaye","year":"2022","unstructured":"Mbaye, B. et al. Endogenous ethanol and triglyceride production by gut Pichia kudriavzevii, Candida albicans and Candida glabrata yeasts in non-alcoholic steatohepatitis. Cells 11, 3390 (2022).","journal-title":"Cells"},{"key":"1089_CR149","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","volume":"13","author":"E Seki","year":"2007","unstructured":"Seki, E. et al. TLR4 enhances TGF-\u03b2 signaling and hepatic fibrosis. Nat. Med. 13, 1324\u20131332 (2007).","journal-title":"Nat. Med."},{"key":"1089_CR150","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2007.04.019","volume":"47","author":"CA Rivera","year":"2007","unstructured":"Rivera, C. A. et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47, 571\u2013579 (2007).","journal-title":"J. Hepatol."},{"key":"1089_CR151","doi-asserted-by":"publisher","first-page":"eabe1692","DOI":"10.1126\/scitranslmed.abe1692","volume":"13","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1\/Notch signaling to determine NASH-induced fibrosis. Sci. Transl Med. 13, eabe1692 (2021).","journal-title":"Sci. Transl Med."},{"key":"1089_CR152","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1089_CR153","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hep.24341","volume":"54","author":"T Csak","year":"2011","unstructured":"Csak, T. et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54, 133\u2013144 (2011).","journal-title":"Hepatology"},{"key":"1089_CR154","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179\u2013188 (2011).","journal-title":"Nat. Med."},{"key":"1089_CR155","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","volume":"74","author":"S Gaul","year":"2021","unstructured":"Gaul, S. et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J. Hepatol. 74, 156\u2013167 (2021).","journal-title":"J. Hepatol."},{"key":"1089_CR156","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179\u2013185 (2012).","journal-title":"Nature"},{"key":"1089_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11744-6","volume":"7","author":"I Pierantonelli","year":"2017","unstructured":"Pierantonelli, I. et al. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. Sci. Rep. 7, 12200 (2017).","journal-title":"Sci. Rep."},{"key":"1089_CR158","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jcmgh.2022.06.007","volume":"14","author":"B Kaufmann","year":"2022","unstructured":"Kaufmann, B. et al. Cell-specific deletion of NLRP3 inflammasome identifies myeloid cells as key drivers of liver inflammation and fibrosis in murine steatohepatitis. Cell Mol. Gastroenterol. Hepatol. 14, 751\u2013767 (2022).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1089_CR159","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/hep.32289","volume":"75","author":"J Remetic","year":"2022","unstructured":"Remetic, J. et al. Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance. Hepatology 75, 1095\u20131109 (2022).","journal-title":"Hepatology"},{"key":"1089_CR160","doi-asserted-by":"publisher","first-page":"12040","DOI":"10.1073\/pnas.90.24.12040","volume":"90","author":"DM Levine","year":"1993","unstructured":"Levine, D. M., Parker, T. S., Donnelly, T. M., Walsh, A. & Rubin, A. L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl Acad. Sci. USA 90, 12040\u201312044 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1089_CR161","doi-asserted-by":"publisher","first-page":"eabe6729","DOI":"10.1126\/science.abe6729","volume":"373","author":"YH Han","year":"2021","unstructured":"Han, Y. H. et al. Enterically derived high-density lipoprotein restrains liver injury through the portal vein. Science 373, eabe6729 (2021).","journal-title":"Science"},{"key":"1089_CR162","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12876-021-01958-4","volume":"21","author":"S Nikeghbalian","year":"2021","unstructured":"Nikeghbalian, S. et al. Correlation between HDL2, HDL3 and serum ferritin levels with fatty liver and NAFLD activity score (NAS) in liver histology of organ donors. BMC Gastroenterol. 21, 405 (2021).","journal-title":"BMC Gastroenterol."},{"key":"1089_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-98","volume":"10","author":"YY Jing","year":"2012","unstructured":"Jing, Y. Y. et al. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med. 10, 98 (2012).","journal-title":"BMC Med."},{"key":"1089_CR164","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canlet.2014.12.019","volume":"358","author":"WT Liu","year":"2015","unstructured":"Liu, W. T. et al. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Lett. 358, 136\u2013143 (2015).","journal-title":"Cancer Lett."},{"key":"1089_CR165","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","volume":"21","author":"DH Dapito","year":"2012","unstructured":"Dapito, D. H. et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504\u2013516 (2012).","journal-title":"Cancer Cell"},{"key":"1089_CR166","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41418-019-0340-7","volume":"27","author":"WT Liu","year":"2020","unstructured":"Liu, W. T. et al. Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts constitutes the hepatocarcinogenesis-associated microenvironment. Cell Death Differ. 27, 85\u2013101 (2020).","journal-title":"Cell Death Differ."},{"key":"1089_CR167","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1002\/cncr.22705","volume":"109","author":"SR Ansari","year":"2007","unstructured":"Ansari, S. R. et al. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 109, 2615\u20132622 (2007).","journal-title":"Cancer"},{"key":"1089_CR168","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1086\/522998","volume":"45","author":"A Safdar","year":"2007","unstructured":"Safdar, A. & Rolston, K. V. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin. Infect. Dis. 45, 1602\u20131609 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"1089_CR169","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/hep.31755","volume":"74","author":"F Barrow","year":"2021","unstructured":"Barrow, F. et al. Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling. Hepatology 74, 704\u2013722 (2021).","journal-title":"Hepatology"},{"key":"1089_CR170","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","volume":"79","author":"E Kotsiliti","year":"2023","unstructured":"Kotsiliti, E. et al. Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J. Hepatol. 79, 296\u2013313 (2023).","journal-title":"J. Hepatol."},{"key":"1089_CR171","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-024-07372-6","volume":"629","author":"Y Miyamoto","year":"2024","unstructured":"Miyamoto, Y. et al. Periportal macrophages protect against commensal-driven liver inflammation. Nature 629, 901\u2013909 (2024).","journal-title":"Nature"},{"key":"1089_CR172","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456 (2021).","journal-title":"Nature"},{"key":"1089_CR173","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li, M. et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology 79, 560\u2013574 (2024).","journal-title":"Hepatology"},{"key":"1089_CR174","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","volume":"8","author":"MA Tincopa","year":"2023","unstructured":"Tincopa, M. A. & Loomba, R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol. Hepatol. 8, 660\u2013670 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1089_CR175","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.21984","volume":"47","author":"IN Guha","year":"2008","unstructured":"Guha, I. N. et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 47, 455\u2013460 (2008).","journal-title":"Hepatology"},{"key":"1089_CR176","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison, S. A. et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 970\u2013985 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1089_CR177","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714\u2013725 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1089_CR178","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","volume":"37","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. Cell Metab. 37, 59\u201368.e3 (2025).","journal-title":"Cell Metab."},{"key":"1089_CR179","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004779","volume":"10","author":"PC Lee","year":"2022","unstructured":"Lee, P. C. et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J. Immunother. Cancer 10, e004779 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1089_CR180","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/hep4.1905","volume":"6","author":"FR Ponziani","year":"2022","unstructured":"Ponziani, F. R. et al. Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma. Hepatol. Commun. 6, 1492\u20131501 (2022).","journal-title":"Hepatol. Commun."},{"key":"1089_CR181","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315\u2013324 (2022).","journal-title":"Nat. Med."},{"key":"1089_CR182","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1002\/ijc.32339","volume":"145","author":"N Iida","year":"2019","unstructured":"Iida, N. et al. Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma. Int. J. Cancer 145, 2701\u20132711 (2019).","journal-title":"Int. J. Cancer"},{"key":"1089_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01751-y","volume":"7","author":"D Zhou","year":"2017","unstructured":"Zhou, D. et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci. Rep. 7, 1529 (2017).","journal-title":"Sci. Rep."},{"key":"1089_CR184","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.759306","volume":"12","author":"L Xue","year":"2022","unstructured":"Xue, L., Deng, Z., Luo, W., He, X. & Chen, Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front. Cell Infect. Microbiol. 12, 759306 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1089_CR185","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","volume":"115","author":"L Craven","year":"2020","unstructured":"Craven, L. et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am. J. Gastroenterol. 115, 1055\u20131065 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"1089_CR186","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep4.1601","volume":"4","author":"JJ Witjes","year":"2020","unstructured":"Witjes, J. J. et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol. Commun. 4, 1578\u20131590 (2020).","journal-title":"Hepatol. Commun."},{"key":"1089_CR187","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2223330","volume":"15","author":"D Stols-Goncalves","year":"2023","unstructured":"Stols-Goncalves, D. et al. Faecal microbiota transplantation affects liver DNA methylation in non-alcoholic fatty liver disease: a multi-omics approach. Gut Microbes 15, 2223330 (2023).","journal-title":"Gut Microbes"},{"key":"1089_CR188","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.cgh.2018.07.022","volume":"17","author":"JS Bajaj","year":"2019","unstructured":"Bajaj, J. S. et al. Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis. Clin. Gastroenterol. Hepatol. 17, 756\u2013765.e3 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1089_CR189","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","volume":"66","author":"G Cammarota","year":"2017","unstructured":"Cammarota, G. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66, 569\u2013580 (2017).","journal-title":"Gut"},{"key":"1089_CR190","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","volume":"39","author":"C Loguercio","year":"2005","unstructured":"Loguercio, C. et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 39, 540\u2013543 (2005).","journal-title":"J. Clin. Gastroenterol."},{"key":"1089_CR191","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","volume":"39","author":"A Alisi","year":"2014","unstructured":"Alisi, A. et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 39, 1276\u20131285 (2014).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1089_CR192","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000315","volume":"6","author":"A Duseja","year":"2019","unstructured":"Duseja, A. et al. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 6, e000315 (2019).","journal-title":"BMJ Open Gastroenterol."},{"key":"1089_CR193","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","volume":"21","author":"PL Chong","year":"2021","unstructured":"Chong, P. L., Laight, D., Aspinall, R. J., Higginson, A. & Cummings, M. H. A randomised placebo controlled trial of VSL#3 probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterol. 21, 144 (2021).","journal-title":"BMC Gastroenterol."},{"key":"1089_CR194","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","volume":"12","author":"VW Wong","year":"2013","unstructured":"Wong, V. W. et al. Treatment of nonalcoholic steatohepatitis with probiotics: a proof-of-concept study. Ann. Hepatol. 12, 256\u2013262 (2013).","journal-title":"Ann. Hepatol."},{"key":"1089_CR195","first-page":"1090","volume":"15","author":"R Aller","year":"2011","unstructured":"Aller, R. et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 15, 1090\u20131095 (2011).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"1089_CR196","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gutjnl-2014-308778","volume":"65","author":"MC Dao","year":"2016","unstructured":"Dao, M. C. et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426\u2013436 (2016).","journal-title":"Gut"},{"key":"1089_CR197","doi-asserted-by":"publisher","first-page":"64","DOI":"10.14715\/cmb\/2021.67.5.9","volume":"68","author":"W Zhu","year":"2022","unstructured":"Zhu, W., Yan, M., Cao, H., Zhou, J. & Xu, Z. Effects of Clostridium butyricum capsules combined with rosuvastatin on intestinal flora, lipid metabolism, liver function and inflammation in NAFLD patients. Cell Mol. Biol. 68, 64\u201369 (2022).","journal-title":"Cell Mol. Biol."},{"key":"1089_CR198","doi-asserted-by":"publisher","first-page":"e01011","DOI":"10.1128\/mBio.01011-14","volume":"5","author":"A Everard","year":"2014","unstructured":"Everard, A., Matamoros, S., Geurts, L., Delzenne, N. M. & Cani, P. D. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db\/db mice. mBio 5, e01011-14 (2014).","journal-title":"mBio"},{"key":"1089_CR199","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.887728","volume":"13","author":"AM Yang","year":"2022","unstructured":"Yang, A. M. et al. Saccharomyces boulardii ameliorates non-alcoholic steatohepatitis in mice induced by a methionine-choline-deficient diet through gut-liver axis. Front. Microbiol. 13, 887728 (2022).","journal-title":"Front. Microbiol."},{"key":"1089_CR200","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/00042737-200306000-00017","volume":"15","author":"M Guslandi","year":"2003","unstructured":"Guslandi, M., Giollo, P. & Testoni, P. A. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 15, 697\u2013698 (2003).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1089_CR201","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.chom.2020.07.007","volume":"28","author":"S Lang","year":"2020","unstructured":"Lang, S. & Schnabl, B. Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host Microbe 28, 233\u2013244 (2020).","journal-title":"Cell Host Microbe"},{"key":"1089_CR202","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1136\/gutjnl-2018-317232","volume":"68","author":"T Hendrikx","year":"2019","unstructured":"Hendrikx, T. et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut 68, 1504\u20131515 (2019).","journal-title":"Gut"},{"key":"1089_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114300","volume":"159","author":"X Huang","year":"2023","unstructured":"Huang, X. et al. Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism. Biomed. Pharmacother. 159, 114300 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1089_CR204","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","volume":"35","author":"Y Ni","year":"2023","unstructured":"Ni, Y. et al. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metab. 35, 1530\u20131547.e8 (2023).","journal-title":"Cell Metab."},{"key":"1089_CR205","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.cmet.2023.07.004","volume":"35","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Yu, J. & Wong, V. W. Vive la resistant starch: a potential treatment for metabolic dysfunction-associated steatohepatitis. Cell Metab. 35, 1491\u20131493 (2023).","journal-title":"Cell Metab."},{"key":"1089_CR206","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/nu10111793","volume":"10","author":"M Krawczyk","year":"2018","unstructured":"Krawczyk, M. et al. Gut permeability might be improved by dietary fiber in individuals with nonalcoholic fatty liver disease (NAFLD) undergoing weight reduction. Nutrients 10, 1793 (2018).","journal-title":"Nutrients"},{"key":"1089_CR207","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","volume":"158","author":"E Scorletti","year":"2020","unstructured":"Scorletti, E. et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology 158, 1597\u20131610.e7 (2020).","journal-title":"Gastroenterology"},{"key":"1089_CR208","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","volume":"18","author":"S Salminen","year":"2021","unstructured":"Salminen, S. et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat. Rev. Gastroenterol. Hepatol. 18, 649\u2013667 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1089_CR209","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nm.4236","volume":"23","author":"H Plovier","year":"2017","unstructured":"Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107\u2013113 (2017).","journal-title":"Nat. Med."},{"key":"1089_CR210","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","volume":"25","author":"C Depommier","year":"2019","unstructured":"Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096\u20131103 (2019).","journal-title":"Nat. Med."},{"key":"1089_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2023.109495","volume":"123","author":"A Brandt","year":"2024","unstructured":"Brandt, A. et al. Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction. J. Nutr. Biochem. 123, 109495 (2024).","journal-title":"J. Nutr. Biochem."},{"key":"1089_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.841132","volume":"13","author":"J Jian","year":"2022","unstructured":"Jian, J. et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids. Front. Pharmacol. 13, 841132 (2022).","journal-title":"Front. Pharmacol."},{"key":"1089_CR213","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","volume":"30","author":"A Abdel-Razik","year":"2018","unstructured":"Abdel-Razik, A. et al. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur. J. Gastroenterol. Hepatol. 30, 1237\u20131246 (2018).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1089_CR214","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.bbrc.2020.05.128","volume":"529","author":"P Wu","year":"2020","unstructured":"Wu, P. et al. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem. Biophys. Res. Commun. 529, 834\u2013838 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1089_CR215","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.23727","volume":"52","author":"UF Leuschner","year":"2010","unstructured":"Leuschner, U. F. et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52, 472\u2013479 (2010).","journal-title":"Hepatology"},{"key":"1089_CR216","first-page":"696","volume":"29","author":"W Zhang","year":"2020","unstructured":"Zhang, W., Tang, Y., Huang, J. & Hu, H. Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: an updated meta-analysis of randomized controlled trials. Asia Pac. J. Clin. Nutr. 29, 696\u2013705 (2020).","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"1089_CR217","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5005\/jp-journals-10018-1434","volume":"14","author":"VS Patel","year":"2024","unstructured":"Patel, V. S. et al. Ursodeoxycholic acid\u2019s effectiveness in the management of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Euroasian J. Hepatogastroenterol. 14, 92\u201398 (2024).","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"1089_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26991","volume":"10","author":"X Li","year":"2024","unstructured":"Li, X. et al. Short-chain fatty acids in nonalcoholic fatty liver disease: new prospects for short-chain fatty acids as therapeutic targets. Heliyon 10, e26991 (2024).","journal-title":"Heliyon"},{"key":"1089_CR219","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/jn\/nxy324","volume":"149","author":"W Fang","year":"2019","unstructured":"Fang, W., Xue, H., Chen, X., Chen, K. & Ling, W. Supplementation with sodium butyrate modulates the composition of the gut microbiota and ameliorates high-fat diet-induced obesity in mice. J. Nutr. 149, 747\u2013754 (2019).","journal-title":"J. Nutr."},{"key":"1089_CR220","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39028-w","volume":"14","author":"L Gan","year":"2023","unstructured":"Gan, L. et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat. Commun. 14, 3215 (2023).","journal-title":"Nat. Commun."},{"key":"1089_CR221","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.cell.2022.07.003","volume":"185","author":"S Federici","year":"2022","unstructured":"Federici, S. et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 185, 2879\u20132898.e24 (2022).","journal-title":"Cell"},{"key":"1089_CR222","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jhep.2021.08.003","volume":"75","author":"CL Hsu","year":"2021","unstructured":"Hsu, C. L., Duan, Y., Fouts, D. E. & Schnabl, B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J. Hepatol. 75, 1465\u20131475 (2021).","journal-title":"J. Hepatol."},{"key":"1089_CR223","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-019-1894-8","volume":"577","author":"HG Hampton","year":"2020","unstructured":"Hampton, H. G., Watson, B. N. J. & Fineran, P. C. The arms race between bacteria and their phage foes. Nature 577, 327\u2013336 (2020).","journal-title":"Nature"},{"key":"1089_CR224","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031698","volume":"7","author":"J Gu","year":"2012","unstructured":"Gu, J. et al. A method for generation phage cocktail with great therapeutic potential. PLoS ONE\u00a07, e31698 (2012).","journal-title":"PLoS ONE"},{"key":"1089_CR225","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051017","volume":"7","author":"AE Kirby","year":"2012","unstructured":"Kirby, A. E. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS ONE\u00a07, e51017 (2012).","journal-title":"PLoS ONE"},{"key":"1089_CR226","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/jac\/dkp360","volume":"64","author":"V Verma","year":"2009","unstructured":"Verma, V., Harjai, K. & Chhibber, S. Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. J. Antimicrob. Chemother. 64, 1212\u20131218 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"1089_CR227","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/v10070351","volume":"10","author":"F Oechslin","year":"2018","unstructured":"Oechslin, F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses 10, 351 (2018).","journal-title":"Viruses"},{"key":"1089_CR228","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3390\/ijms23042181","volume":"23","author":"Y Shi","year":"2022","unstructured":"Shi, Y., Wang, G., Lau, H. C. & Yu, J. Metagenomic sequencing for microbial DNA in human samples: emerging technological advances. Int. J. Mol. Sci. 23, 2181 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1089_CR229","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-022-01762-z","volume":"9","author":"V Meslier","year":"2022","unstructured":"Meslier, V. et al. Benchmarking second and third-generation sequencing platforms for microbial metagenomics. Sci. Data 9, 694 (2022).","journal-title":"Sci. Data"},{"key":"1089_CR230","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12864-018-4637-6","volume":"19","author":"MB Pereira","year":"2018","unstructured":"Pereira, M. B., Wallroth, M., Jonsson, V. & Kristiansson, E. Comparison of normalization methods for the analysis of metagenomic gene abundance data. BMC Genom. 19, 274 (2018).","journal-title":"BMC Genom."},{"key":"1089_CR231","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303943","volume":"13","author":"M Lucchetti","year":"2024","unstructured":"Lucchetti, M. et al. An organ-on-chip platform for simulating drug metabolism along the gut-liver Axis. Adv. Healthc. Mater. 13, e2303943 (2024).","journal-title":"Adv. Healthc. Mater."},{"key":"1089_CR232","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ccell.2024.07.005","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. Cancer Cell 42, 1386\u20131400.e8 (2024).","journal-title":"Cancer Cell"},{"key":"1089_CR233","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/gutjnl-2020-323877","volume":"70","author":"F Asnicar","year":"2021","unstructured":"Asnicar, F. et al. Blue poo: impact of gut transit time on the gut microbiome using a novel marker. Gut 70, 1665\u20131674 (2021).","journal-title":"Gut"},{"key":"1089_CR234","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.93","volume":"1","author":"HM Roager","year":"2016","unstructured":"Roager, H. M. et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nat. Microbiol. 1, 16093 (2016).","journal-title":"Nat. Microbiol."},{"key":"1089_CR235","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1126\/science.aad3503","volume":"352","author":"G Falony","year":"2016","unstructured":"Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560\u2013564 (2016).","journal-title":"Science"},{"key":"1089_CR236","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2022-328166","volume":"72","author":"N Prochazkova","year":"2023","unstructured":"Prochazkova, N. et al. Advancing human gut microbiota research by considering gut transit time. Gut 72, 180\u2013191 (2023).","journal-title":"Gut"},{"key":"1089_CR237","doi-asserted-by":"publisher","first-page":"fnab042","DOI":"10.1093\/femsle\/fnab042","volume":"368","author":"G Raba","year":"2021","unstructured":"Raba, G., Adamberg, S. & Adamberg, K. Acidic pH enhances butyrate production from pectin by faecal microbiota. FEMS Microbiol. Lett. 368, fnab042 (2021).","journal-title":"FEMS Microbiol. Lett."},{"key":"1089_CR238","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1136\/gutjnl-2021-326264","volume":"71","author":"NL Ting","year":"2022","unstructured":"Ting, N. L., Lau, H. C. & Yu, J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 71, 1412\u20131425 (2022).","journal-title":"Gut"},{"key":"1089_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104967","volume":"100","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy. EBioMedicine 100, 104967 (2024).","journal-title":"EBioMedicine"},{"key":"1089_CR240","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","volume":"72","author":"W Fong","year":"2023","unstructured":"Fong, W. et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut 72, 2272\u20132285 (2023).","journal-title":"Gut"},{"key":"1089_CR241","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hep.28572","volume":"65","author":"F Del Chierico","year":"2017","unstructured":"Del Chierico, F. et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65, 451\u2013464 (2017).","journal-title":"Hepatology"},{"key":"1089_CR242","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764\u2013775 (2016).","journal-title":"Hepatology"},{"key":"1089_CR243","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","volume":"54","author":"V Ratziu","year":"2011","unstructured":"Ratziu, V. et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol. 54, 1011\u20131019 (2011).","journal-title":"J. Hepatol."},{"key":"1089_CR244","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"1089_CR245","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793\u2013801 (2019).","journal-title":"J. Hepatol."},{"key":"1089_CR246","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"1089_CR247","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223\u2013238 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1089_CR248","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S2468-1253(24)00049-9","volume":"9","author":"The Lancet Gastroenterology Hepatology.","year":"2024","unstructured":"The Lancet Gastroenterology Hepatology. Resmetirom for NASH: balancing promise and prudence. Lancet Gastroenterol. Hepatol. 9, 273 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1089_CR249","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20131124 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1089_CR250","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N. Engl. J. Med. 389, 998\u20131008 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1089_CR251","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol. Hepatol. 8, 1080\u20131093 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1089_CR252","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque, S. M. et al. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N. Engl. J. Med. 385, 1547\u20131558 (2021).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01089-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01089-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01089-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:43:55Z","timestamp":1757209435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-025-01089-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":252,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1038\/s41575-025-01089-1","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"4 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}